KyungDong Pharm home
Prescription Medicines

Esocarbo Tab. 40/600mg

Product Category
Gastroesophageal reflux disease (GERD) treatment
Active Ingredients
Esomeprazole magnesium trihydrate, precipitated calcium carbonate
Appearance
Pink, oblong, film-coated tablets
Reimbursement Code
648104620
View Regulatory Information on the MFDS Portal ↗
1. Ingredient content
1 tablet
- Active ingredients: Esomeprazole Magnesium Trihydrate (USP) 44.5mg (40mg as Esomeprazole), Precipitated Calcium Carbonate (KP) 600mg
- Additives (animal-derived ingredients): Anhydrous lactose (cow, milk)
- Other additives: sodium hydroxide, opadry pink (03B54445), sodium starch glycolate, pregelatinized starch, crospovidone, talc, povidone, polysorbate 80, polyethylene glycol 6000, sodium stearyl fumarate

2. Effectiveness
Gastroesophageal reflux disease (GERD)
- Treatment of erosive reflux esophagitis
- Long-term maintenance therapy to prevent recurrence in patients with esophagitis
- Treatment for symptoms of gastroesophageal reflux disease without esophagitis

3. Dosage and dosage
Take this medication on an empty stomach at least 1 hour before a meal.
When taking this medicine, swallow it as is with at least half a glass of water. Do not take with drinks other than water. This medicine should not be chewed or crushed. This medicine 20/600mg and 40/600mg contain 20 and 40mg of esomeprazole respectively, but be careful because the amount of calcium carbonate in two 20/600mg tablets and one 40/600mg tablet is not the same.
1. Adult
Gastroesophageal reflux disease (GERD).
- Treatment of erosive reflux esophagitis: Administer 40/600 mg once a day for 4 weeks. For patients whose esophagitis is not cured or whose symptoms persist, take the medication for 4 more weeks.
- Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20/600 mg once a day
- Symptomatic treatment of gastroesophageal reflux disease without esophagitis
· Once a day, 20/600mg once. If symptoms are not controlled after 4 weeks, additional treatment is required.
· Once symptoms are alleviated, subsequent symptoms are controlled by administering 20/600 mg once a day.
· In adults, 20/600 mg can be administered once a day, whenever necessary. For patients at high risk of developing gastric or duodenal ulcers due to NSAID treatment, it is not recommended to administer the drug as often as needed to continuously control symptoms.
2. Liver dysfunction: There is no need to adjust the dose in patients with mild to moderate liver dysfunction. For patients with severe hepatic impairment, the dose of this drug should not exceed 20/600 mg.

4. Precautions for use
1. Do not administer to the following patients.
1) Patients with a history of hypersensitivity to this drug, its components, or benzimidazoles
2) Patients receiving atazanavir and nelfinavir (see interaction section)
3) Nursing mothers
4) Patients taking rilpivirine-containing preparations (see interaction section)
5) Patients with severe (severe symptoms) hypercalcemia and patients with severe (severe symptoms) hypercalciuria
6) Patients with hyperparathyroidism or hypothyroidism
7) Patients with severe (severe symptoms) renal impairment
8) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

2. Administer with caution to the following patients.
1) Patients with liver impairment
2) Elderly people
3) Patients with severe digestive tract ulcers
4) Patients with renal impairment
5) Patients with cardiac dysfunction and pulmonary dysfunction
6) Constipation patients

3. Adverse reactions
1) Esomeprazole
(1) The following adverse reactions were confirmed or suspected in clinical trials and post-marketing surveillance for esomeprazole. There was no dose correlation. Adverse reactions were classified according to frequency (often >1/100, <1/10; sometimes >1/1,000, <1/100; rarely >1/10,000, <1/1,000; very rare <1/10,000).
- Blood and lymphatic system: rare leukopenia, thrombocytopenia, very rare agranulocytosis, pancytopenia
- Immune system: Rare hypersensitivity reactions such as fever, angioedema, anaphylactic reaction/shock, etc.
- Metabolism/Nutrition: Sometimes peripheral edema, rarely hyponatremia, very rarely hypomagnesemia (severe hypomagnesemia may cause hypocalcemia. Hypomagnesemia may also cause hypokalemia.)
- Mental system: sometimes insomnia, rarely agitation, mental confusion, depression, very rarely aggression, hallucinations
- Nervous system: frequent headache, occasional dizziness, paresthesia, drowsiness, rarely taste disturbance
- Vision: Rarely blurred vision
- Auditory and labyrinthine systems: sometimes dizziness (vertigo)
- Respiratory system: Rarely bronchospasm
- Gastrointestinal system: pancreatitis, frequent abdominal pain, constipation, diarrhea, abdominal distension, nausea and vomiting, sometimes dry mouth, rarely stomatitis, gastrointestinal candidiasis, very rarely microscopic colitis
- Hepatobiliary system: sometimes increased liver enzymes, rarely hepatitis with or without jaundice, very rarely liver failure, encephalopathy in patients with pre-existing liver disease.
- Skin and subcutaneous tissue: Occasionally dermatitis, itching, rash, urticaria, rarely hair loss, photosensitivity, very rarely erythema multiforme, mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome), toxic epidermal necrolysis (Riel syndrome), acute generalized pustulosis erythroderma, drug reaction with increased eosinophilia and systemic symptoms (DRESS syndrome)
- Musculoskeletal system: fractures rarely, joint pain, muscle pain, very rarely muscle weakness
- Kidney and urinary system: very rarely interstitial nephritis
- Reproductive system: Very rarely, gynecomastia
- Whole body and administration site: Rarely, asthenia and increased sweating
- Infection: Clostridium difficile diarrhea (frequency unknown)
(2) In addition, the following adverse reactions were reported to be related or possibly related to esomeprazole with an incidence of less than 1%.
- Whole body: abdominal distension, allergic reaction, back pain, chest pain, substernal chest pain, facial edema, facial flushing, fatigue, fever, influenza-like disorder, general edema, leg edema, malaise, pain, stiffness, asthenia, peripheral edema
- Cardiovascular system: flushing, hypertension, tachycardia
- Endocrine system: goiter
- Digestive system: Colon hypersensitivity, worsening constipation, indigestion, dysphagia, gastrointestinal dysplasia, epigastric pain, belching, esophageal disorder, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased blood gastrin, tongue disorders, tongue edema, ulcerative stomatitis, vomiting
- Hearing: earache, tinnitus
- Blood system: anemia, hypochromic anemia, cervical lymphadenopathy, nosebleeds, leukocytosis, leukopenia, thrombocytopenia
- Liver: bilirubinemia, abnormal liver function, increased ALT, increased AST
- Metabolism/Nutrition: Diabetes, hyperuricemia, hyponatremia, increased ALP, dry mouth, vitamin B12 deficiency, weight gain, weight loss
- Musculoskeletal system: worsening arthritis, arthropathy, cramps, fibromyalgia syndrome, hernia, polymyalgia rheumatica, arthralgia
- Mental nervous system: Anorexia, apathy, increased appetite, confusion, worsening depression, hypertonia, agitation, decreased sensation, erectile dysfunction, insomnia, migraine, worsening migraine, sleep disorder, tremor, dizziness, vertigo, visual field defect, paresthesia, drowsiness.
- Reproductive system: dysmenorrhea, menstrual disorders, vaginitis
- Respiratory system: worsening asthma, cough, difficulty breathing, laryngeal edema, pharyngitis, rhinitis, sinusitis
- Skin/Appendixes: Acne, anal itching, rash, erythematous rash, maculopapular rash, angioedema, dermatitis, itching, urticaria, increased sweating
- Special senses: otitis media, abnormal sense of smell, loss of taste, loss of sense of taste
- Urinary system: urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, frequent urination, candidiasis, genital candidiasis, polyuria.
- Vision: Conjunctivitis, visual abnormality
- Adverse reactions discovered on endoscopy: duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyps or nodules, Barrett's esophagus, mucous membrane discoloration, hernia
(3) The following are adverse reactions reported through post-marketing surveillance of proton pump inhibitors. Because these adverse reactions are voluntarily reported from an unspecified population, it is not always possible to reliably predict their incidence or establish a causal relationship with drug administration.
- Immune system: Systemic lupus erythematosus
- Skin and subcutaneous tissue system: Cutaneous lupus erythematosus
- Gastrointestinal system: gastric gland polyp
- Metabolism and nutritional system: hypocalcemia, hypokalemia
(4) Rhabdomyolysis: Rhabdomyolysis may occur, so observe carefully. If symptoms including muscle pain, asthenia, increased creatinine kinase (creatine phosphatase), and increased blood and urine myoglobin appear, administration should be discontinued and appropriate measures should be taken.
2) Precipitated calcium carbonate
1) Digestive system: Nausea, constipation, or diarrhea may occur while taking this drug, and in rare cases, stomach upset.
Reboundary secretion of acid may occur.
2) Metabolic abnormalities: Hypercalcemia and alkalosis may occur with high doses.
3) Long-term/mass administration: Renal stones and urinary stones may occur.
4) Hypersensitivity: Itching may occur.

4. General precautions
1) This drug may alleviate the symptoms of malignant tumor or delay the diagnosis, so if there are warning symptoms of suspected malignant tumor (unintentional significant weight loss, recurrent vomiting, difficulty swallowing, hematemesis, melena, etc.) and gastric ulcer is present or suspected, the drug must be administered after confirming that it is not malignant.
2) When treating with this drug for a long period of time (especially more than 1 year), patients should be examined regularly.
3) Patients taking this drug when necessary are advised to consult a doctor if there are any changes in symptoms. If this drug is prescribed for on-demand administration, interactions with other drugs due to fluctuations in blood concentration of this drug should be taken into consideration.
4) When stomach acidity decreases due to proton pump inhibitors, the number of bacteria normally present in the gastrointestinal tract increases. Treatment with this medicine may slightly increase the risk of infections of the gastrointestinal tract caused by bacteria such as Salmonella, Campylobacter, and Clostridium difficile. This is associated with an increased risk of Clostridium difficile diarrhea, and several observational studies have reported that this risk is particularly increased in hospitalized patients. This diagnosis should be considered when diarrhea symptoms do not improve. Clostridium difficile diarrhea has been reported during use of almost all antibacterial agents.
5) Some overseas epidemiological studies have reported that proton pump inhibitor treatment may be associated with an increased risk of hip, wrist, and spine fractures. The risk of fracture was increased in patients receiving higher doses than the recommended dose and in patients using the drug for long-term use of more than 1 year.
Although the causal relationship between omeprazole and esomeprazole and osteoporotic fractures has not been determined, appropriate clinical monitoring is recommended according to the latest clinical guidelines for patients at risk of developing osteoporosis and osteoporotic fractures.
6) Hypomagnesemia was rarely reported in patients treated with proton pump inhibitors for more than 3 months, and was most common in patients treated for more than 1 year. For most patients, magnesium supplementation and discontinuation of proton pump inhibitor administration are necessary to treat hypomagnesemia. Patients requiring long-term treatment or taking concomitant medications such as digoxin or drugs that cause hypomagnesemia (e.g. diuretics) require periodic monitoring of magnesium levels, including at the start of treatment. Serious adverse reactions include rigidity, arrhythmias, and seizures.
7) The decrease in gastric acidity caused by the administration of this drug increases the concentration of serum chromogranin A (CgA). Therefore, people taking this drug may experience false positive results in neuroendocrine tumor diagnostic tests. Administration of this drug should be temporarily discontinued at least 14 days before the CgA test. If the test value exceeds the upper reference limit, retesting should be considered. When tests are performed repeatedly (e.g., monitoring), concentration measurements should be performed in the same laboratory because reference ranges differ between laboratories.
8) Methotrexate: There have been literature reports that when proton pump inhibitors and methotrexate are used together (mainly when using high doses, see precautions for the use of methotrexate), the serum concentration of methotrexate and/or its metabolites increases and persists, leading to methotrexate toxicity. When high doses of methotrexate are used, temporary discontinuation of the proton pump inhibitor may be considered (see Interaction section).
9) During treatment, the progress should be observed sufficiently and this drug should be administered at the minimum dose and appropriate treatment period depending on the symptoms.
10) Skin and systemic lupus erythematosus: Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking proton pump inhibitors. These cases occurred newly or due to worsening of existing autoimmune diseases. Most cases of lupus erythematosus caused by proton pump inhibitors were cutaneous lupus erythematosus.
The most common form of cutaneous lupus erythematosus reported in patients taking proton pump inhibitors is subacute cutaneous lupus erythematosus, which occurs within weeks to years of continuous drug treatment in patients ranging from infants to the elderly. In general, histological results showed no organ invasion. spot
Systemic lupus erythematosus has been reported less commonly than cutaneous lupus erythematosus in patients taking proton pump inhibitors. Proton pump inhibitor-related systemic lupus erythematosus usually shows milder symptoms than non-drug-induced systemic lupus erythematosus. Systemic lupus erythematosus mainly occurs within a few days to several years after initial drug treatment in young adults to the elderly. The majority of patients presented with a rash, but arthralgia and cytopenias were also reported.
Do not take proton pump inhibitors for longer than medically indicated. If a patient taking this drug develops symptoms or signs consistent with cutaneous lupus erythematosus or systemic lupus erythematosus, stop taking the drug and refer the patient to an appropriate specialist for evaluation. Most patients improved simply by discontinuing proton pump inhibitors within 4 to 12 weeks. Serological tests (e.g., antinuclear antibody (ANA)) may be positive, and high serological test results may take longer to resolve than clinical symptoms.
11) Fundic gland polyps: The use of proton pump inhibitors is associated with an increased risk of fundic gland polyps, especially when used for a long period of more than a year. Among patients using proton pump inhibitors, most patients who developed gastric fundic polyps were asymptomatic and discovered accidentally through endoscopy. Proton pump inhibitors should be used for the shortest period of time according to the symptoms being treated.
12) Severe skin adverse reactions: Severe skin adverse reactions (SCAR), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with increased eosinophilia and systemic symptoms (DRESS syndrome), and acute generalized erythroderma pustulosis (AGEP), have been reported when using proton pump inhibitors. At the first sign of severe skin adverse reactions or hypersensitivity reactions, treatment with this drug should be discontinued and further evaluation considered.

5. Interaction
1) Esomeprazole
(1) Due to the decrease in gastric acidity during administration of this drug, the absorption of drugs whose absorption mechanism is affected by gastric acidity may increase or decrease. As with other acid secretion suppressants or antacids, the absorption of ketoconazole, itraconazole, and erlotinib may be reduced and the absorption of digoxin may be increased during administration of this drug. In healthy volunteers, coadministration of omeprazole (20 mg per day) with digoxin increased the bioavailability of digoxin by 10% (up to 30% in 2 out of 10 volunteers). Esomeprazole is an isomer of omeprazole. Therefore, when this drug is administered in combination with digoxin, the patient's condition must be monitored.
(2) Esomeprazole is metabolized by CYP2C19 and CYP3A4. Additionally, esomeprazole inhibits CYP2C19, the main metabolic enzyme of this drug. When coadministered with drugs metabolized by CYP2C19, such as diazepam, citalopram, imipramine, clomipramine, phenytoin, and warfarin, the plasma concentration of these drugs may increase, so a dose reduction of these drugs may be necessary. Co-administration of 30 mg of diazepam, a CYP2C19 substrate, and esomeprazole decreased the clearance of diazepam by 45%. Coadministration of 40 mg of phenytoin and esomeprazole in patients with epilepsy increased the minimum plasma concentration of phenytoin by 13%. Monitor phenytoin plasma concentrations when starting or discontinuing treatment with this drug. Omeprazole (40 mg administered once daily) increased the Cmax and AUCτ of voriconazole (CYP2C19 substrate) by 15% and 41%, respectively.
In clinical trials, when 40 mg of esomeprazole was co-administered to patients taking warfarin, the coagulation time was within the normal range. However, in post-marketing surveillance, several clinically significant increases in INR and prothrombin time were reported during co-administration of the two drugs, which can lead to abnormal bleeding and even death. Therefore, monitoring is necessary when starting or discontinuing co-administration of this drug with warfarin or other coumarin derivatives.
(3) Esomeprazole is metabolized by CYP2C19 and CYP3A4. Coadministration of esomeprazole and the CYP3A4 inhibitor clarithromycin (500 mg twice daily) doubles the AUC of this drug. Co-administration of this drug with CYP2C19 or CYP3A4 inhibitors may more than double the exposure of this drug. Voriconazole, a CYP2C19 and CYP3A4 inhibitor, increased the AUCτ of omeprazole by 280%. For this reason, there is no need to adjust the dose of this drug. However, dose adjustment should be considered in patients with severe liver dysfunction and patients requiring long-term treatment.
(4) Drugs known to induce CYP2C19, CYP3A4, or both (e.g., rifampicin and St. John's wort) may decrease esomeprazole serum concentrations by increasing esomeprazole metabolism. Avoid coadministration of this drug with rifampicin or St. John's wort.
(5) In addition to esomeprazole, omeprazole also acts as an inhibitor of CYP2C19. In a crossover study, when 40 mg of omeprazole was administered to healthy volunteers, the Cmax and AUC of cilostazol increased by 18% and 26%, respectively, and the Cmax and AUC of one of the active metabolites of cilostazol increased by 29% and 69%, respectively.
(6) Co-administration of omeprazole (40 mg once daily) and atazanavir 300 mg/ritonavir 100 mg in healthy volunteers decreased the exposure of atazanavir (approximately 75% decrease in AUC, Cmax, and Cmin). Dosing of atazanavir 400 mg four times daily cannot offset the effect of omeprazole on atazanavir exposure. Proton pump inhibitors, including this drug, cannot be administered together with atazanavir.
(7) Omeprazole has been reported to interact with several antiviral agents. Other than this reported interaction, the clinical significance and mechanism have not been determined. Reduced gastric acidity during omeprazole administration may alter the absorption of antiviral agents. Another possible mechanism of interaction is CYP2C19, and decreased serum levels of antiviral agents such as atazanavir and nelfinavir have been reported when coadministered with omeprazole, and coadministration is not recommended. In addition, increased serum levels have been reported with antiviral agents such as saquinavir. There are also antiviral agents whose serum levels do not change when administered in combination with omeprazole. Omeprazole and esomeprazole have similar pharmacodynamic/pharmacokinetic properties and should not be coadministered with antiviral drugs such as atazanavir and nelfinavir.
(8) When 40 mg of cisapride and esomeprazole were co-administered to healthy volunteers, the AUC of cisapride was increased by 32% and the elimination half-life was prolonged by 31%, but there was no significant increase in peak plasma concentration. This interaction did not alter the effects of cisapride on cardiac electrophysiology. In other words, in addition to the slight prolongation of the QTc interval caused by cisapride alone, the QTc interval was not further prolonged by co-administration of this drug and cisapride.
(9) Esomeprazole did not have a clinically significant effect on the pharmacokinetics of amoxicillin or quinidine.
(10) Short-term studies evaluating the co-administration of esomeprazole with naproxen or rofecoxib showed no clinically relevant pharmacokinetic interactions.
(11) From the results of a study in healthy volunteers, clopidogrel (initial dose 300 mg/maintenance dose 75 mg per day) and esomeprazole (orally administered 40 mg per day) appeared to have a pharmacokinetic/pharmacodynamic interaction, which was shown to reduce platelet aggregation by an average of 14% and to reduce exposure to the active metabolite of clopidogrel by an average of 40%. Based on these results, esomeprazole and clopidogrel should not be administered together.
(12) In adverse reaction case reports, population pharmacokinetic studies, and retrospective studies, it has been reported that when methotrexate (usually used in high doses, see precautions for the use of methotrexate) and proton pump inhibitors are used together, the serum concentration of methotrexate and/or its metabolite, hydroxymethotrexate, increases and is maintained, leading to methotrexate toxicity. However, formal drug interaction studies have not been conducted on high-dose methotrexate and proton pump inhibitors (see General Precautions).
(13) If this drug is used together with tacrolimus, the serum level of tacrolimus may increase.
(14) Co-administration of this drug and rilpivirine may decrease the plasma concentration of rilpivirine (increased gastric pH), so co-administration should not be performed. This may reduce the therapeutic effect of rilpivirine.
2) Precipitated calcium carbonate
(1) Administer with caution as the absorption and excretion of concomitant drugs may be affected by the adsorption effect of this drug or the increase in pH of the digestive tract and body fluids.
(2) When used in combination with a large amount of milk, milk alkalinity syndrome (hypercalcemia, azotemia, alkalosis, etc.) may occur, so observe thoroughly and discontinue administration if these symptoms appear.
(3) Do not co-administer as it may inhibit the absorption of tetracyacline antibiotics.
(4) Be careful because hypercalcemia is likely to occur when administered in combination with vitamin D and thiazide diuretics.

6. Administration to pregnant women
There are limited data on exposure to esomeprazole during pregnancy. As a result of animal testing, no direct or indirect harmful effects were found in relation to embryo/fetal development. Animal testing of the racemic mixture showed no direct or indirect harmful effects on pregnancy, parturition, or postpartum development. However, caution should be exercised when prescribing this drug to pregnant women.

7. Administration to nursing mothers
It is not known whether esomeprazole passes into human breast milk. Since studies have not been conducted on nursing mothers, this drug should not be administered during breastfeeding.

8. Treatment in case of overdose
Symptoms associated with planned overdose (limited experience with esomeprazole doses of 240 mg/day) are transient. There were no significant problems when 80 mg of esomeprazole was administered once. No specific antidote is known. Esomeprazole is not dialyzed because it has a very high protein binding rate. Therefore, in case of overdose, symptomatic treatment and general maintenance treatment should be used.

9. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

10. Information for experts
1) Pharmacological action
- Esomeprazole: As a proton pump inhibitor (PPI), it suppresses gastric acid secretion by inhibiting H+/K+-ATPase.
- Precipitated calcium carbonate: A slightly alkaline drug that neutralizes stomach acid and reduces stomach acidity.
2) Pharmacokinetic/pharmacodynamic information
- Esoka Correction 20/600mg
In a randomized, open-label, repeated-dose, crossover clinical trial targeting 44 healthy adults, when esomeprazole/precipitated calcium carbonate 20/600mg combination and esomeprazole 20mg single agent were administered orally once a day for 7 days, the geometric mean ratio of the AUCtau and ss of esomeprazole for the combination compared to the single agent was 0.9359, and the 90% confidence interval was 0.9359. It was observed as 0.8861?0.9885. In addition, the geometric mean ratio of Cmax, ss for combination drugs compared to single drugs was observed to be 1.11930, and the 90% confidence interval was 1.0977-1.2965.
In a randomized, open-label, repeated-dose, crossover clinical trial targeting 44 healthy adults, after oral administration of esomeprazole/precipitated calcium carbonate 20/600mg combination and esomeprazole 20mg single agent once daily for 7 days, the 24-hour integrated gastric acidity reduction rate (%) was 80.86% for esomeprazole/precipitated calcium carbonate and esomeprazole single agent, respectively. It was found to be 78.28%, and the geometric mean ratio of combination drugs to single drugs was 1.0330, and the 90% confidence interval was 0.9783-1.0907.
- Esoka Correction 40/600mg
In a randomized, open-label, repeated-dose, crossover clinical trial targeting 36 healthy adults, when esomeprazole/precipitated calcium carbonate 40/600 mg combination and esomeprazole 40 mg single agent were administered orally once a day for 7 days, the geometric mean ratio of the AUCtau and ss of esomeprazole for the combination compared to the single agent was 0.9849, and the 90% confidence interval was 0.9849. It was observed as 0.9332?1.0396. In addition, the geometric mean ratio of Cmax, ss for combination drugs compared to single drugs was observed to be 1.0838, and the 90% confidence interval was 0.9838-1.1939.
In a randomized, open-label, repeated-dose, crossover clinical trial targeting 35 healthy adults, the 24-hour integrated gastric acidity reduction rate (%) after oral administration of esomeprazole/precipitated calcium carbonate 40/600 mg combination and esomeprazole 40 mg single agent once daily for 7 days was 85.62% for esomeprazole/precipitated calcium carbonate and esomeprazole single agent, respectively. It was found to be 84.00%, and the geometric mean ratio of combination drugs to single drugs was 1.0193, and the 90% confidence interval was observed to be 0.9849-1.0549.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
28 tablets/bottle, 28 tablets/box (7 tablets/PTP

7. Period of use
24 months from date of manufacture

Product Updates

Total 2items

No.Product NameDetailsDate of ChangeDownload
2Esocarbo Tab. 40/600mgPrecautions for use2024.03.27PDF0090_202101157_Precautions for use (Esoka correction 40_600mg).pdf
1Esocarbo Tab. 40/600mgPrecautions for use2023.05.14PDF0088_202101157_Precautions for use (Esoka correction 40_600mg).pdf